EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program

Andreia Rosário iD, Ana Sousa iD, Joana Marinho-Dias iD, Rui Medeiros iD, Cláudia Lobo, Luís Leça, Nuno Coimbra iD, Fernando Tavares, Inês Baldaque, Gabriela Martins iD, Paula Monteiro iD, Rui Henrique iD und 1 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Andreia Rosário und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology & Viral Pathology Group, Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto …. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Papillomavirus Infections, Atypical Squamous Cells of the Cervix. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer prevention is based on primary prevention with vaccines against Human Papillomavirus (HPV) and secondary prevention by screening with High‐Risk‐HPV (Hr‐HPV) detection. Since 2017, cervical cancer screening in women aged 25−60 years has been performed in Portugal using Hr‐HPV detection, followed by cytology in Hr‐HPV‐positive cases. Herein we report the prevalence of Hr‐HPV genotypes and cytological abnormalities among 462 401 women (mean age: 43.73 ± 10.79; median age: 45; range: 24−66 years) that participated in the Regional Cervical Cancer Screening Program of the Northern Region of Portugal, performed between August 2016 and December 2021. Overall, we describe a prevalence rate of 12.50% for Hr‐HPV varying from 20.76% at age 25% to 8.32% at age 64. The five most common Hr‐HPV genotypes identified were HPV‐68 (16.09%), HPV‐31 (15.30%), HPV‐51 (12.96%), HPV‐16 (11.06%), and HPV‐39 (11.01%). The prevalence of Hr‐HPV included in the nonavalent vaccine (HPV‐9valent) was 55.00% ranging from 47.78% to 59.18% across different age groups. Considering positive Hr‐HPV cases, 65.68% had a Negative for Intraepithelial Lesion or Malignancy (NILM) cytology, 20.83% atypical squamous cells of undetermined significance (ASC‐US), 8.85% Low‐Grade Squamous Intraepithelial Lesion (LSIL), 1.65% High‐Grade Squamous Intraepithelial Lesion (HSIL), 2.85% ASC‐H, 0.09% Atypical Glandular Cells, 0.02% Adenocarcinomas, and 0.02% Squamous Cell Carcinoma (SCC). Our analysis revealed that HPV‐9val genotypes were responsible for 52.13% NILM, 59.21% ASC‐US, 55.06% LSIL, 90.14% HSIL, 83.50% ASC‐H, and 100.00% SCC. Furthermore, multiple Hr‐HPV infections (risk ratio [RR] = 1.46; 95% confidence interval [CI] 1.34−1.58), HPV‐16/18 (RR = 5.16; 95% CI 4.75−5.93), or HPV‐9val genotypes (RR = 5.23; 95% CI 4.68−5.85) were associated with a significant risk of developing > HSIL ( p < 0.001). To date, this is the largest study on Hr‐HPV genotyping in cervical cancer screening that includes data from a complete cycle of the screening program. Our findings suggest a high prevalence of HPV‐9valent genotypes and a significant association with an increased risk of developing > HSIL. This constitutes important data for health authorities, which may help define the future of vaccination and cervical cancer screening strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellUterine Cervical NeoplasmsPapillomavirus InfectionsAtypical Squamous Cells of the CervixUterine Cervical DysplasiaAdultAlphapapillomavirusEarly Detection of CancerFemaleHuman Papillomavirus VirusesHuman papillomavirus 18Middle AgedPapillomaviridaeHuman papillomavirus 16PortugalHumansGenotype

Stichwörter der Autor:innen

Human Papillomaviruscervical cancergenotypingprevalencescreeningvaccine

Autor:innen und Institutionen

  • Molecular Oncology & Viral Pathology Group, Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC…
  • Department of Pathology and Laboratory Medicine, Clinical Pathology Service, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal.
  • Department of Health Sciences, Escola Superior de Saúde do Instituto Politécnico de Bragança, Bragança, Portugal.
  • Research Department, Portuguese League Against Cancer (LPCC-NRNorte), Porto, Portugal.
  • Department of Pathology and Laboratory Medicine, Anatomic Pathology Service, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal.
  • Administração Regional de Saúde do Norte I.P., Porto, Portugal.

ORCID-Profile: Andreia Rosário, Ana Sousa, Joana Marinho-Dias, Rui Medeiros, Nuno Coimbra, Gabriela Martins, Paula Monteiro, Rui Henrique, Hugo Sousa

Zitieren

APA

Rosário, A., Sousa, A., Marinho-Dias, J., Medeiros, R., Lobo, C., Leça, L., Coimbra, N., Tavares, F., Baldaque, I., Martins, G., Monteiro, P., Henrique, R., & Sousa, H. (2023). Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program. Journal of Medical Virology. https://doi.org/10.1002/jmv.28414

Vancouver

Rosário A, Sousa A, Marinho-Dias J, Medeiros R, Lobo C, Leça L, et al. Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program. Journal of Medical Virology. 2023. doi:10.1002/jmv.28414

BibTeX
@article{Rosrio2023,
  author = {Rosário, Andreia and Sousa, Ana and Marinho-Dias, Joana and Medeiros, Rui and Lobo, Cláudia and Leça, Luís and Coimbra, Nuno and Tavares, Fernando and Baldaque, Inês and Martins, Gabriela and Monteiro, Paula and Henrique, Rui and Sousa, Hugo},
  title = {Impact of high‐risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real‐world data from regional cervical cancer screening program},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28414}
}
Kostenlos starten →